---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-084039"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2022-12-30T23:59:59+00:00"
generated_at: "2026-06-20T21:31:20.425571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics raises $10M in private placement of shares and warrants at $5.00 per unit

## Summary
- Gross proceeds of $10M from sale of 2M shares (or equivalents) and warrants for 2.5M shares at $5.00 per unit.
- Warrants exercisable at $5.00 per share for 5.5 years from issuance; pre-funded warrants at $0.001 per share.
- Expected closing on January 3, 2023; H.C. Wainwright acts as exclusive placement agent.
- Net proceeds to fund further development of product candidates and for working capital.
- Company to file resale registration statement within 15 days; must be effective within 45–75 days.

## SEC filing metadata
- accession: 0001213900-22-084039
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2022-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390022084039/0001213900-22-084039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390022084039/ea171028-8k_hoththera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-084039
- JSON: https://secwatch.observer/filing/0001213900-22-084039.json
- Plain text: https://secwatch.observer/filing/0001213900-22-084039.txt

## Key facts
- Material Agreements
  Hoth Therapeutics, Inc. entered into Purchase Agreement with an accredited investor valued at aggregate gross proceeds of approximately $10 million (effective 2022-12-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an accredited investor
  - Value: aggregate gross proceeds of approximately $10 million
  - Effective: 2022-12-29
  source text: On December 29, 2022, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which it agreed to sell an aggregate of (i) 140,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), (ii) warrants (the “Pre-Funded Warrants”) to purchase up to 1,860,000 shares (the “Pre-funded Warrant Shares”) of Common Stock and (iii) warrants (the “Common Stock Warrants” and together with the Pre-Funded Warrants, the “Warrants”) to purchase up to 2,500,000 shares (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrant Shares, the “Registrable Securities”) of Common Stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each Pre-Funded Warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390022084039/0001213900-22-084039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.